Clinical Trial Update: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) [Phase 3]

View source ↗

Summary

Phase III study evaluating Panzyga for primary infection prophylaxis in chronic lymphocytic leukemia with hypogammaglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Panzyga (intravenous immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Status: COMPLETED